Impax Settles IP Row With J&J Over Generic Concerta

Law360, New York (September 14, 2012, 7:23 PM EDT) -- Impax Laboratories Inc. on Friday inked a deal with two Johnson & Johnson subsidiaries, giving Impax licensing rights to produce generic versions of the attention deficit hyperactivity disorder drug Concerta and putting to rest a lengthy patent infringement battle against the generic drugmaker.

Under the agreement reached with Alza Corp. and Janssen Pharmaceuticals Inc., Impax may sell generic Concerta tablets in 18-, 27-, 36- and 54-milligram dosages effective July 14. Impax's settlement also authorizes Teva Pharmaceuticals USA Inc. to market Impax’s generic Concerta tablets.

Janssen owns...
To view the full article, register now.